dlg3312

DLG3312 is a **novel GLP-1 analog** synthesized as a dimer of glucagon-like peptide-1 (GLP-1), covalently linked at the C-terminal lysine residue[1][6][9]. It is designed to extend the biological half-life of GLP-1 and enhance its anti-diabetic effects, retaining full agonist activity at the GLP-1 receptor. DLG3312 has demonstrated potent glucose-lowering capacity in animal models of type 2 diabetes, reducing blood glucose and HbA1c, and strongly stimulating insulin secretion in a dose-dependent manner. This analog shows similar efficacy to liraglutide in preclinical models but features a simpler preparation process. Moreover, DLG3312 can be used in advanced drug delivery systems (such as sustained-release nanoparticles) to prolong its action and reduce injection frequency[3][5][7].